JP2019529402A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529402A5
JP2019529402A5 JP2019513787A JP2019513787A JP2019529402A5 JP 2019529402 A5 JP2019529402 A5 JP 2019529402A5 JP 2019513787 A JP2019513787 A JP 2019513787A JP 2019513787 A JP2019513787 A JP 2019513787A JP 2019529402 A5 JP2019529402 A5 JP 2019529402A5
Authority
JP
Japan
Prior art keywords
compound
composition
group
use according
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019513787A
Other languages
English (en)
Japanese (ja)
Other versions
JP7046381B2 (ja
JP2019529402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073747 external-priority patent/WO2018054959A1/en
Publication of JP2019529402A publication Critical patent/JP2019529402A/ja
Publication of JP2019529402A5 publication Critical patent/JP2019529402A5/ja
Application granted granted Critical
Publication of JP7046381B2 publication Critical patent/JP7046381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019513787A 2016-09-20 2017-09-20 リポタンパク質代謝障害の治療のための化合物 Expired - Fee Related JP7046381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670733 2016-09-20
DKPA201670733 2016-09-20
PCT/EP2017/073747 WO2018054959A1 (en) 2016-09-20 2017-09-20 Compounds for treatment of lipoprotein metabolism disorders

Publications (3)

Publication Number Publication Date
JP2019529402A JP2019529402A (ja) 2019-10-17
JP2019529402A5 true JP2019529402A5 (enExample) 2020-11-05
JP7046381B2 JP7046381B2 (ja) 2022-04-04

Family

ID=59974406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513787A Expired - Fee Related JP7046381B2 (ja) 2016-09-20 2017-09-20 リポタンパク質代謝障害の治療のための化合物

Country Status (9)

Country Link
US (2) US11173177B2 (enExample)
EP (1) EP3515455B1 (enExample)
JP (1) JP7046381B2 (enExample)
CN (1) CN110494145A (enExample)
AU (1) AU2017329799A1 (enExample)
CA (1) CA3035875A1 (enExample)
DK (1) DK3515455T3 (enExample)
ES (1) ES2871783T3 (enExample)
WO (1) WO2018054959A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
KR102137147B1 (ko) * 2018-07-16 2020-07-24 경희대학교 산학협력단 벤질 알파-d-갈락토피라노사이드 또는 (-)-세코이소라리시레시놀-9'-o-베타-d-글루코피라노사이드를 포함하는 당뇨병 예방 또는 치료용 조성물
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
WO2021122793A1 (en) * 2019-12-17 2021-06-24 Norinvent Ab Sulfated disaccharides as enhancers of transmucosal drug uptake
KR20230057410A (ko) 2020-08-25 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료
CN116854752B (zh) * 2022-03-28 2026-08-04 南开大学 肝素三糖结构化合物及其制药应用
CN116270507A (zh) * 2023-03-02 2023-06-23 青岛海洋生物医药研究院股份有限公司 一种含脂蛋白脂酶刺激剂的舌下含片及其制备方法和应用
CN119708089B (zh) * 2023-09-27 2026-06-26 南开大学 一种磺酸化三糖及其制备方法和治疗应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
WO1993007167A1 (en) 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5366473A (en) 1992-08-18 1994-11-22 Ultrasonic Sensing And Monitoring Systems, Inc. Method and apparatus for applying vascular grafts
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2584927T7 (es) * 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Derivados de oligosacáridos sulfatados novedosos
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9拮抗劑類
KR101293278B1 (ko) 2009-10-29 2013-08-09 주식회사 한독 신규 혈관누출 차단제
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2014005224A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
AU2014235430A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders

Similar Documents

Publication Publication Date Title
JP2020517694A5 (enExample)
JP2025037925A5 (enExample)
JP2019535672A5 (enExample)
JP2008505157A5 (enExample)
JP2022533069A5 (enExample)
JP2021500403A5 (enExample)
JP2008520742A5 (enExample)
JP2024167182A5 (enExample)
JP2019531279A5 (enExample)
JP2020502047A5 (enExample)
JP2011520815A5 (enExample)
JP2015051994A5 (enExample)
JP2016534148A5 (enExample)
WO2017176974A1 (en) Biodegradable amino-ester nanomaterials for nucleic acid delivery
JP2012504133A5 (enExample)
JP2013520502A5 (enExample)
JP2023504184A5 (enExample)
JP2021105002A5 (enExample)
JP2010511626A5 (enExample)
JP2010077141A5 (enExample)
JP2008544074A5 (enExample)
JP2018135343A5 (enExample)
JP2018528273A5 (enExample)
JP2016531126A5 (enExample)
JP2003306481A5 (enExample)